Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Asymchem Laboratories (Tianjin) Co., Ltd. Class H ( (HK:6821) ).
Asymchem Laboratories (Tianjin) Co., Ltd. reported revenue of RMB6.67 billion for 2025, a 14.91% increase from the prior year, with gross profit rising 16.46% and gross margin edging up to 41.59%. Net profit attributable to shareholders climbed 19.35% to RMB1.13 billion, while adjusted net profit surged 56.09% to RMB1.25 billion, lifting the adjusted net margin to 18.79%.
The company’s improved profitability was reflected in basic and diluted earnings per share, which rose 17.66% to RMB3.16, underscoring stronger operational performance and margin expansion. The board proposed a final dividend of RMB13.00 per 10 shares, totaling about RMB467.6 million, signaling confidence in cash generation and offering a higher direct return to shareholders, subject to approval at the annual general meeting.
The most recent analyst rating on (HK:6821) stock is a Hold with a HK$90.00 price target. To see the full list of analyst forecasts on Asymchem Laboratories (Tianjin) Co., Ltd. Class H stock, see the HK:6821 Stock Forecast page.
More about Asymchem Laboratories (Tianjin) Co., Ltd. Class H
Asymchem Laboratories (Tianjin) Co., Ltd. is a China-based pharmaceutical services company listed in Hong Kong that operates through a group structure. It focuses on providing contract development and manufacturing solutions for the life sciences sector, generating revenue primarily from specialized laboratory and production services for global drug makers.
Average Trading Volume: 298,824
Technical Sentiment Signal: Buy
Current Market Cap: HK$39.77B
For detailed information about 6821 stock, go to TipRanks’ Stock Analysis page.